A0089 Paradigm 1 - a multi-center phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – a first interim review

European Urology 2026

View at publisher

Authors: N. Shore, Michael G. Oefelein, A. Shah, Daniel E. Zainfeld, L. Deban, J.B. Holz

DOI: 10.1016/s0302-2838(26)00154-5

Cited by: 0

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary Tract Infections Management Urinary Bladder and Prostate Research